{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T18:30:20Z","timestamp":1771266620957,"version":"3.50.1"},"reference-count":63,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T00:00:00Z","timestamp":1730505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diseases"],"abstract":"<jats:p>Background: Chronic myeloid leukemia (CML) is one of the most commonly found types of myeloproliferative neoplasms, characterized by increased proliferation of granulocytic cells without losing their differentiation ability. Imatinib, a tyrosine kinase inhibitor (TKI), can be effectively used as therapy for CML. However, Imatinib can affect bone turnover thus having clinical implications on the bones of CML patients undergoing long-term Imatinib therapy. However, parameters that can accurately describe the bone condition in CML patients receiving Imatinib still need further study. A combination of imaging techniques such as bone mineral density (BMD) and bone turnover activity markers such as C-terminal telopeptide of type I collagen (CTX-1) and osteocalcin has the potential to be used as monitoring parameters for bone density abnormalities in CML patients receiving Imatinib. Objectives: This article explains the rationale for using BMD, CTX-1, and osteocalcin as monitoring parameters of bone remodeling in CML patients receiving Imatinib. Results: First, the physiological process of bone turnover will be explained. Then, we describe the role of tyrosine kinase in bone metabolism. Next, the impact of Imatinib on BMD, CTX-1, and osteocalcin will be explained. Conclusion: The assessment of bone health of CML patients on Imatinib should include both BMD tests and bone turnover marker assays such as CTX-1 and osteocalcin.<\/jats:p>","DOI":"10.3390\/diseases12110275","type":"journal-article","created":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T05:41:23Z","timestamp":1730698883000},"page":"275","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Bone Mineral Density, C-Terminal Telopeptide of Type I Collagen, and Osteocalcin as Monitoring Parameters of Bone Remodeling in CML Patients Undergoing Imatinib Therapy: A Basic Science and Clinical Review"],"prefix":"10.3390","volume":"12","author":[{"given":"Nurita","family":"Indarwulan","sequence":"first","affiliation":[{"name":"Subspeciality Program in Hematology and Medical Oncology Division, Department of Internal Medicine, Dr. Soetomo General Academic Hospital, Surabaya 60286, Indonesia"},{"name":"Subspeciality Program in Hematology and Medical Oncology Division, Department of Internal Medicine, Faculty of Medicine, Airlangga University, Surabaya 60132, Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Merlyna","family":"Savitri","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Department of Internal Medicine, Dr. Soetomo General Academic Hospital, Surabaya 60286, Indonesia"},{"name":"Division of Hematology and Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Airlangga University, Surabaya 60132, Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ami","family":"Ashariati","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Department of Internal Medicine, Dr. Soetomo General Academic Hospital, Surabaya 60286, Indonesia"},{"name":"Division of Hematology and Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Airlangga University, Surabaya 60132, Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siprianus Ugroseno Yudho","family":"Bintoro","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Department of Internal Medicine, Dr. Soetomo General Academic Hospital, Surabaya 60286, Indonesia"},{"name":"Division of Hematology and Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Airlangga University, Surabaya 60132, Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Noor","family":"Diansyah","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Department of Internal Medicine, Dr. Soetomo General Academic Hospital, Surabaya 60286, Indonesia"},{"name":"Division of Hematology and Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Airlangga University, Surabaya 60132, Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Putu Niken Ayu","family":"Amrita","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Department of Internal Medicine, Dr. Soetomo General Academic Hospital, Surabaya 60286, Indonesia"},{"name":"Division of Hematology and Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Airlangga University, Surabaya 60132, Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pradana Zaky","family":"Romadhon","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Department of Internal Medicine, Dr. Soetomo General Academic Hospital, Surabaya 60286, Indonesia"},{"name":"Division of Hematology and Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Airlangga University, Surabaya 60132, Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,11,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1835091","DOI":"10.1155\/2019\/1835091","article-title":"Effect of Imatinib on Bone Marrow Morphology and Angiogenesis in Chronic Myeloid Leukemia","volume":"2019","author":"Pandey","year":"2019","journal-title":"Adv. Hematol."},{"key":"ref_2","first-page":"357027","article-title":"Imatinib: A Breakthrough of Targeted Therapy in Cancer","volume":"2014","author":"Iqbal","year":"2014","journal-title":"Chemother. Res. Pract."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.leukres.2013.02.005","article-title":"Effect of long-term imatinib on bone in adults with chronic myelogenous leukemia and gastrointestinal stromal tumors","volume":"37","author":"Berman","year":"2013","journal-title":"Leuk. Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"846","DOI":"10.4103\/2230-8210.192914","article-title":"Bone turnover markers: An emerging tool in the management of osteoporosis","volume":"20","author":"Shetty","year":"2016","journal-title":"Indian. J. Endocrinol. Metab."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clinbiochem.2022.09.002","article-title":"Current use of bone turnover markers in the management of osteoporosis","volume":"109\u2013110","author":"Brown","year":"2022","journal-title":"Clin. Biochem."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.fertnstert.2019.10.005","article-title":"Human skeletal physiology and factors affecting its modeling and remodeling","volume":"112","author":"Nandiraju","year":"2019","journal-title":"Fertil. Steril."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"131","DOI":"10.2215\/CJN.04151206","article-title":"Normal bone anatomy and physiology","volume":"3","author":"Clarke","year":"2008","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13287-018-0798-0","article-title":"Extracellular matrix stiffness controls the osteogenic differentiation of mesenchymal stem cells mediated by integrin \u03b15","volume":"9","author":"Sun","year":"2018","journal-title":"Stem Cell Res. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Palumbo, C., and Ferretti, M. (2021). The Osteocyte: From \u201cPrisoner\u201d to \u201cOrchestrator\u201d. J. Funct. Morphol. Kinesiol., 6.","DOI":"10.3390\/jfmk6010028"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1146\/annurev-pathmechdis-031521-040919","article-title":"Osteoclasts, Master Sculptors of Bone","volume":"18","author":"Veis","year":"2023","journal-title":"Annu. Rev. Pathol. Mech. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.14245\/ns.2346966.483","article-title":"Bone Remodeling and Modeling: Cellular Targets for Antiresorptive and Anabolic Treatments, Including Approaches Through the Parathyroid Hormone (PTH)\/PTH-Related Protein Pathway","volume":"20","author":"Martin","year":"2023","journal-title":"Neurospine"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12018-023-09286-9","article-title":"The Macrophage\u2019s Role on Bone Remodeling and Osteogenesis: A Systematic Review","volume":"21","author":"Orvalho","year":"2023","journal-title":"Clin. Rev. Bone Min. Metab."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1002\/jcb.24691","article-title":"Osteoblast Adhesion Dynamics: A Possible Role for ROS and LMW-PTP","volume":"115","author":"Fernandes","year":"2014","journal-title":"J. Cell Biochem."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Liu, Y., Ruan, X., Li, J., Wang, B., Chen, J., Wang, X., and Tu, X. (2022). The Osteocyte Stimulated by Wnt Agonist SKL2001 Is a Safe Osteogenic Niche Improving Bioactivities in a Polycaprolactone and Cell Integrated 3D Module. Cells, 11.","DOI":"10.3390\/cells11050831"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"101129","DOI":"10.1016\/j.bonr.2021.101129","article-title":"Osteocyte Wnt\/\u03b2-catenin pathway activation upon mechanical loading is altered in ovariectomized mice","volume":"15","author":"Jackson","year":"2021","journal-title":"Bone Rep."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Vuoti, E., Lehenkari, P., Tuukkanen, J., Glumoff, V., and Kylm\u00e4oja, E. (2023). Osteoclastogenesis of human peripheral blood, bone marrow, and cord blood monocytes. Sci. Rep., 13.","DOI":"10.1038\/s41598-023-30701-0"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"De Leon-Oliva, D., Barrena-Bl\u00e1zquez, S., Jim\u00e9nez-\u00c1lvarez, L., Fraile-Martinez, O., Garc\u00eda-Montero, C., L\u00f3pez-Gonz\u00e1lez, L., and Ortega, M.A. (2023). The RANK\u2013RANKL\u2013OPG System: A Multifaceted Regulator of Homeostasis, Immunity, and Cancer. Medicina, 59.","DOI":"10.3390\/medicina59101752"},{"key":"ref_18","first-page":"341","article-title":"Bone mineral density\u2014Frequently asked questions","volume":"35","author":"Phillips","year":"2006","journal-title":"Aust. Fam. Physician"},{"key":"ref_19","first-page":"9","article-title":"Bone-mineral density: Clinical significance, methods of quantification and forensic applications","volume":"9","author":"Kranioti","year":"2019","journal-title":"Res. Rep. Forensic Med. Sci."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Francisco, I., Nunes, C., Pereira, F., Travassos, R., Ribeiro, M.P., Marques, F., McEvoy, M., Santos, M., Oliveira, C., and Marto, C.M. (2023). Bone Mineral Density through DEXA and CBCT: A Systematic Review with Meta-Analysis. Appl. Sci., 13.","DOI":"10.3390\/app13105962"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Chen, Y.P., Chan, W.P., Zhang, H.W., Tsai, Z.R., Peng, H.C., Huang, S.W., Jang, Y.-C., and Kuo, Y.-J. (2024). Automated osteoporosis classification and T -score prediction using hip radiographs via deep learning algorithm. Ther. Adv. Musculoskelet. Dis., 16.","DOI":"10.1177\/1759720X241237872"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.joca.2024.03.019","article-title":"Characterization of c-terminal telopeptide of type I collagen (ctx) species in human plasma and serum using high resolution mass spectrometry","volume":"32","author":"Demeuse","year":"2024","journal-title":"Osteoarthr. Cartil."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"A531","DOI":"10.1016\/j.jval.2016.09.1073","article-title":"Assessment of CTX-1 Bone Biomarker as An Indicator of Antiresorptive Therapy Efficacy and of Persistence In A Fracture Liaison Service","volume":"19","author":"Bellemare","year":"2016","journal-title":"Value Health"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/j.joca.2019.02.046","article-title":"Biomarkers of bone and cartilage turnover CTX-I and CTX-II predict total joint replacements in osteoarthritis","volume":"27","author":"Karsdal","year":"2019","journal-title":"Osteoarthr. Cartil."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0009-8981(99)00251-X","article-title":"Comparison of the analytical and clinical performance characteristics of an N-MID versus an intact osteocalcin immunoradiometric assay","volume":"294","author":"Takahashi","year":"2000","journal-title":"Clin. Chim. Acta"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"846480","DOI":"10.1155\/2013\/846480","article-title":"Endocrine Actions of Osteocalcin","volume":"2013","author":"Patti","year":"2013","journal-title":"Int. J. Endocrinol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Kuo, T.R., and Chen, C.H. (2017). Bone biomarker for the clinical assessment of osteoporosis: Recent developments and future perspectives. Biomark. Res., 18.","DOI":"10.1186\/s40364-017-0097-4"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00223-014-9931-y","article-title":"Osteocalcin: An Osteoblast-Derived Polypeptide Hormone that Modulates Whole Body Energy Metabolism","volume":"96","author":"Conigrave","year":"2015","journal-title":"Calcif. Tissue Int."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1373\/clinchem.2016.259085","article-title":"Bone Turnover Markers in the Diagnosis and Monitoring of Metabolic Bone Disease","volume":"63","author":"Greenblatt","year":"2017","journal-title":"Clin. Chem."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41413-022-00190-4","article-title":"Mechanical regulation of bone remodeling","volume":"10","author":"Wang","year":"2022","journal-title":"Bone Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/PL00005830","article-title":"Serum CTX: A New Marker of Bone Resorption That Shows Treatment Effect More Often Than Other Markers Because of Low Coefficient of Variability and Large Changes with Bisphosphonate Therapy","volume":"66","author":"Rosen","year":"2000","journal-title":"Calcif. Tissue Int."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s00774-015-0734-7","article-title":"An overview of osteocalcin progress","volume":"34","author":"Li","year":"2016","journal-title":"J. Bone Min. Metab."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.bone.2011.04.017","article-title":"Intermittent injections of osteocalcin improve glucose metabolism and prevent type 2 diabetes in mice","volume":"50","author":"Ferron","year":"2012","journal-title":"Bone"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"5266","DOI":"10.1073\/pnas.0711119105","article-title":"Osteocalcin differentially regulates \u03b2 cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice","volume":"105","author":"Ferron","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.4161\/cc.24929","article-title":"Intermittent injections of osteocalcin reverse autophagic dysfunction and endoplasmic reticulum stress resulting from diet-induced obesity in the vascular tissue via the NF\u03baB-p65-dependent mechanism","volume":"12","author":"Zhou","year":"2013","journal-title":"Cell Cycle"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1677\/ERC-10-0082","article-title":"Endocrine side effects of broad-acting kinase inhibitors","volume":"17","author":"Lodish","year":"2010","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"R247","DOI":"10.1530\/ERC-12-0400","article-title":"Effects of tyrosine kinase inhibition on bone metabolism: Untargeted consequences of targeted therapies","volume":"21","author":"Farooki","year":"2014","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Matsubara, T., Yasuda, K., Mizuta, K., Kawaue, H., and Kokabu, S. (2022). Tyrosine Kinase Src Is a Regulatory Factor of Bone Homeostasis. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23105508"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Ryu, K.-Y., Pokhrel, N.K., Jung, H.-J., Kim, H.J., Seok, J., Kim, T.-Y., Kim, H.J., Lee, J.H., Kim, J.-Y., and Kim, Y.-G. (2024). Mer tyrosine kinase regulates bone metabolism, and its deficiency partially ameliorates periodontitis- and ovariectomy-induced bone loss in mice. JBMR Plus., 8.","DOI":"10.1093\/jbmrpl\/ziad014"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.4049\/jimmunol.1700582","article-title":"c-Src\u2013Dependent and \u2013Independent Functions of Matk in Osteoclasts and Osteoblasts","volume":"200","author":"Kim","year":"2018","journal-title":"J. Immunol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1210\/jc.2012-2426","article-title":"Prospective Histomorphometric and DXA Evaluation of Bone Remodeling in Imatinib-Treated CML Patients: Evidence for Site-Specific Skeletal Effects","volume":"98","author":"Vandyke","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Id Boufker, H., Lagneaux, L., Najar, M., Piccart, M., Ghanem, G., Body, J.J., and Journ\u00e9, F. (2010). The Src inhibitor dasatinib accelerates the differentiation of human bone marrow-derived mesenchymal stromal cells into osteoblasts. BMC Cancer, 10.","DOI":"10.1186\/1471-2407-10-298"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/978-3-319-91442-8_5","article-title":"Cabozantinib: Multi-kinase Inhibitor of MET, AXL, RET, and VEGFR2","volume":"211","year":"2018","journal-title":"Recent Results Cancer Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1210\/jc.2010-2771","article-title":"Endocrine Effects of the Tyrosine Kinase Inhibitor Vandetanib in Patients Treated for Thyroid Cancer","volume":"96","author":"Brassard","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Xiong, J., Piemontese, M., Onal, M., Campbell, J., Goellner, J.J., Dusevich, V., Bonewald, L., Manolagas, S.C., and O\u2019brien, C.A. (2015). Osteocytes, not Osteoblasts or Lining Cells, are the Main Source of the RANKL Required for Osteoclast Formation in Remodeling Bone. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0138189"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1210\/jc.2012-4085","article-title":"Kinase Inhibitors: Adverse Effects Related to the Endocrine System","volume":"98","author":"Lodish","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s11523-011-0197-2","article-title":"Tyrosine kinase inhibitor-induced hypothyroidism: Incidence, etiology, and management","volume":"6","author":"Brown","year":"2011","journal-title":"Target. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1007\/s00784-010-0456-0","article-title":"PTH(1-34)-induced changes in RANKL and OPG expression by human PDL cells modify osteoclast biology in a co-culture model with RAW 264.7 cells","volume":"15","year":"2011","journal-title":"Clin. Oral. Investig."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"68","DOI":"10.3109\/s10165-006-0460-z","article-title":"The role of c-Src kinase in the regulation of osteoclast function","volume":"16","author":"Miyazaki","year":"2006","journal-title":"Mod. Rheumatol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1002\/ijc.26034","article-title":"Antitumor effect of sunitinib against skeletal metastatic renal cell carcinoma through inhibition of osteoclast function","volume":"130","author":"Maita","year":"2012","journal-title":"Int. J. Cancer."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ejphar.2006.09.007","article-title":"Imatinib mesylate (Gleevec\u00ae) enhances mature osteoclast apoptosis and suppresses osteoclast bone resorbing activity","volume":"551","author":"Gallet","year":"2006","journal-title":"Eur. J. Pharmacol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1182\/blood-2007-07-104281","article-title":"Long-term imatinib therapy promotes bone formation in CML patients","volume":"111","author":"Fitter","year":"2008","journal-title":"Blood"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa051140","article-title":"Altered Bone and Mineral Metabolism in Patients Receiving Imatinib Mesylate","volume":"354","author":"Berman","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/ajh.23155","article-title":"Secondary hyperparathyroidism but stable bone-mineral density in patients with chronic myeloid leukemia treated with imatinib","volume":"87","author":"Standal","year":"2012","journal-title":"Am. J. Hematol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"4334","DOI":"10.1182\/blood-2005-09-3568","article-title":"Imatinib as a potential antiresorptive therapy for bone disease","volume":"107","author":"Dewar","year":"2006","journal-title":"Blood"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.3109\/10428194.2012.760734","article-title":"Bone metabolism during long-term treatment with imatinib","volume":"54","author":"Horne","year":"2013","journal-title":"Leuk. Lymphoma"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.3109\/10428194.2013.772608","article-title":"Imatinib and chronic myeloid leukemia: Close to the bone","volume":"54","author":"Terpos","year":"2013","journal-title":"Leuk. Lymphoma"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/ped.13136","article-title":"Adverse effects of imatinib in children with chronic myelogenous leukemia","volume":"59","author":"Choeyprasert","year":"2017","journal-title":"Pediatr. Int."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"CR721","DOI":"10.12659\/MSM.883599","article-title":"Changes in bone metabolic parameters in children with chronic myeloid leukemia on imatinib treatment","volume":"18","author":"Jaeger","year":"2012","journal-title":"Med. Sci. Monit."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Tauer, J.T., Hofbauer, L.C., Jung, R., Gerdes, S., Glauche, I., Erben, R.G., and Suttorp, M. (2015). Impact of Long-Term Exposure to the Tyrosine Kinase Inhibitor Imatinib on the Skeleton of Growing Rats. Eaves CJ, editor. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0131192"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jocd.2019.03.004","article-title":"Consensus Statement on the Use of Bone Turnover Markers for Short-Term Monitoring of Osteoporosis Treatment in the Asia-Pacific Region","volume":"24","author":"Wu","year":"2021","journal-title":"J. Clin. Densitom."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Hong, L., Liu, D., Wu, F., Wang, M., Cen, Y., and Ma, L. (2020). Correlation between bone turnover markers and bone mineral density in patients undergoing long-term anti-osteoporosis treatment: A systematic review and meta-analysis. Appl. Sci., 10.","DOI":"10.3390\/app10030832"},{"key":"ref_63","unstructured":"Sitepu, E. (2024, September 17). BioRender [Internet]. BioRender; 21 October 2024. Available online: https:\/\/biorender.com\/j80q330."}],"container-title":["Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-9721\/12\/11\/275\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:27:05Z","timestamp":1760113625000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-9721\/12\/11\/275"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,2]]},"references-count":63,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["diseases12110275"],"URL":"https:\/\/doi.org\/10.3390\/diseases12110275","relation":{},"ISSN":["2079-9721"],"issn-type":[{"value":"2079-9721","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,2]]}}}